摘要：11.Habib AA, et al. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive

参考文献

1.常婷.中国重症肌无力诊断和治疗指南(2020版)[J].中国神经免疫学和神经病学杂志,2021,28(01):1-12.

2.Gilhus NE, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019 May 2;5(1):30.

3.Li Y, et al. Serological diagnosis of myasthenia gravis and its clinical significance. Ann Transl Med. 2023 Apr 15;11(7):290.

4.Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024 Feb;20(2):84-98.

5.Rodolico C, et al. MuSK-Associated Myasthenia Gravis: Clinical Features and Management. Front Neurol. 2020 Jul 23;11:660.

6.Claytor B, et al. Myasthenic crisis. Muscle Nerve. 2023 Jul;68(1):8-19.

7. Evoli A, et al.Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008;1132:76-83.

8. Murai H, et al.The Japanese clinical guidelines 2022 for myasthenia gravisand Lambert–Eaton myasthenic syndrome. Clinical and Experimental Neuroimmunology 14 (2023): 19 - 27.

9. Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016 Jul 26;87(4):419-25.

10.Bril V, et al. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2021 Feb 9;96(6):e853-e865.

11.Habib AA, et al. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Ther Adv Neurol Disord. 2024 Sep 12;17:17562864241273036.

[CN-RZ-2500065 有效期截止：2027年6月] 本内容仅供医疗卫生专业人士阅读，所含信息不应代替医疗卫生专业人士提供的医疗建议，也不建议医疗卫生专业人士超出说明书范围使用所涉及的药物。

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

来源：医脉通神经科